Perkins Coie Trust Co purchased a new stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,000 shares of the medical equipment provider’s stock, valued at approximately $137,000.
Other large investors have also added to or reduced their stakes in the company. Personal Wealth Partners purchased a new position in shares of Zimmer Biomet during the 2nd quarter valued at about $26,000. TRUE Private Wealth Advisors purchased a new position in shares of Zimmer Biomet during the 2nd quarter valued at about $26,000. Allworth Financial LP raised its holdings in shares of Zimmer Biomet by 65.0% during the 3rd quarter. Allworth Financial LP now owns 203 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 80 shares in the last quarter. Coastal Investment Advisors Inc. raised its holdings in shares of Zimmer Biomet by 271.0% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 256 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 187 shares in the last quarter. Finally, Private Ocean LLC raised its holdings in shares of Zimmer Biomet by 34.8% during the 2nd quarter. Private Ocean LLC now owns 310 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 80 shares in the last quarter. 87.83% of the stock is currently owned by hedge funds and other institutional investors.
ZBH has been the topic of a number of research reports. Stifel Nicolaus set a $155.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a report on Tuesday, September 17th. Zacks Investment Research raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $149.00 price objective on the stock in a report on Saturday, August 31st. Wells Fargo & Co raised their price objective on Zimmer Biomet from $150.00 to $158.00 and gave the company an “outperform” rating in a report on Monday, September 9th. BTIG Research raised Zimmer Biomet from a “neutral” rating to a “buy” rating and set a $158.00 price objective on the stock in a report on Monday. Finally, Morgan Stanley raised their price objective on Zimmer Biomet from $143.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $145.40.
ZBH traded up $2.43 on Friday, hitting $136.50. 26,417 shares of the company were exchanged, compared to its average volume of 1,065,429. The firm has a fifty day simple moving average of $137.15 and a two-hundred day simple moving average of $127.08. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.56 and a current ratio of 1.19. Zimmer Biomet Holdings Inc has a 12 month low of $96.99 and a 12 month high of $143.57. The stock has a market capitalization of $26.94 billion, a PE ratio of 17.85, a price-to-earnings-growth ratio of 2.49 and a beta of 1.16.
Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.02. The business had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.98 billion. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. Zimmer Biomet’s revenue for the quarter was down .9% compared to the same quarter last year. During the same period last year, the company earned $1.92 EPS. On average, equities analysts expect that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be given a $0.24 dividend. The ex-dividend date is Friday, September 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.70%. Zimmer Biomet’s dividend payout ratio is currently 12.57%.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Featured Story: Cryptocurrencies
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.